Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32217611.
- Also identified by DOI 10.1158/1078-0432.CCR-20-0097.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Matched pre-/posttreatment tissue biopsies from patients with <i>EGFR</i>-mutant non-small cell lung cancer demonstrate that histologic transformations, including both small-cell carcinoma and squamous transformation, are unexpectedly common among patients progressing on first-line osimertinib. The study highlights the key role of tissue testing and underscores the need for innovative therapeutic approaches to prevent, rather than treat, resistance.<i>See related article by Schoenfeld et al., p. 2654</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Lung Neoplasms